Moderna says facility near Montreal could be operational by end of ’24

Article content material

MONTREAL — Moderna says development of its new mRNA vaccine manufacturing facility within the Montreal space will start later this yr, with manufacturing anticipated to start by the top of 2024.

Article content material

The vaccine producer is asserting that it has agreed to buy land in a biotechnology park in Laval, Que., a northern suburb of Montreal, to function the positioning of its biomanufacturing facility.

The Massachusetts-based firm says the positioning is right as a consequence of its proximity to a famend analysis institute, the Institut nationwide de la recherche scientifique.

Moderna introduced in April that it might construct a manufacturing facility within the Montreal space that may have the ability to produce 100 million doses of mRNA vaccines a yr.

The power is anticipated to provide vaccines not solely in opposition to COVID-19 but in addition focusing on varied respiratory viruses, together with influenza and respiratory syncytial virus, or RSV.

The corporate says the power is anticipated to be operational by the top of 2024, “topic to planning and regulatory approvals.”

“This location affords great synergies to Moderna as a consequence of its proximity to a famend analysis institute, along with becoming the necessities of the venture and its significance to all Canadians and Quebecers,” the corporate stated in a information launch. “We’re happy to have discovered the best website for the anticipated development of our mRNA vaccine manufacturing facility.”